Skip to main content

WHO advisers recommend against Gilead’s remdesivir for treating COVID-19

Shares of Gilead Sciences Inc. fell in after-hours trading Thursday after a World Health Organization panel recommended against doctors using the drug remdesivir to treat coronavirus patients.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.